Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab +/- Cobimetinib in Unresectable Cholangiocarcinoma
NCT03201458Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cobimetinib in cholangiocarcinoma (CCA) and gallbladder carcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression Free Survival at 1 year. Started Feb 2018; status: completed.
02
Drugs
cobimetinib
03
Conditions
cholangiocarcinoma (CCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT03201458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201458.